A Phase 2a, Single-Arm Study to Investigate the Efficacy and Safety of LY3541860 in Adult Participants With Moderately to Severely Active Rheumatoid Arthritis
Latest Information Update: 10 Mar 2025
Price :
$35 *
At a glance
- Drugs LY 3541860 (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Eli Lilly and Company
- 10 Mar 2025 New trial record